Drug Approval | August 12, 2025
Boehringer’s lung cancer medicine gets FDA approval
FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC
FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
The submission is supported by positive results from the Phase 3 AMPLIFY trial
Vasograin Plus represents a major advancement in the treatment of migraine
Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint
cSCC is one of the most common cancers in the U.S. and globally
he new version features a streamlined sample-to-analysis workflow, built-in HRD detection, faster turnaround, and lower tissue requirements
The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins
Subscribe To Our Newsletter & Stay Updated
